Patents by Inventor Xuechao GAO

Xuechao GAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230021840
    Abstract: Embodiments of the present invention relate to use of a GP73 inhibitor in preparation of a drug for treating diabetes. In the embodiments of the present invention, the inventor finds that GP73 plays a key role in blood glucose regulation, and in particular, finds that soluble GP73 can specifically bind to glucagon to form a complex, enhances the blood glucose-rising function and gluconeogenesis function of glucagon and prolongs the half-life of glucagon; and finds soluble GP73 can activate the glucose production in liver and/or kidney and a gluconeogenesis signaling pathway in a glucagon-independent manner. Based on the blood glucose regulation effect of the GP73 described above, the inventor also proves through animal experiments: the GP73 inhibitor can reduce the blood glucose level and glycated hemoglobin level of diabetic mice and have a protective effect on islet ? cells, and thereby having the effect of treating diabetes.
    Type: Application
    Filed: September 7, 2022
    Publication date: January 26, 2023
    Inventors: Changqing LIN, Zhiwei SUN, Qi GAO, Shuang QIE, Lei XU, JING LI, Jianbo LIN, Hengqi ZHU, Fei ZHENG, Xuechao LIU
  • Publication number: 20220306640
    Abstract: A compound of formula (I-a): wherein the symbols are defined in the specification, and which has a strong DDR1 inhibitory activity, and can be a therapeutic agent for DDR1-related diseases, for example, a cancer, a kidney disease, a cardiovascular disease, a central nervous system disease, or fibrosis.
    Type: Application
    Filed: September 4, 2020
    Publication date: September 29, 2022
    Inventors: Yota NISHIOKA, Masakuni KURONO, Rena NISHIZAWA, Balachandra BANDODKAR, Xuechao GAO, Zhilong WAN, Ranran LV, Kevin DOYLE, Michael GOLDSMITH
  • Patent number: 11384451
    Abstract: The invention relates to a crucible for crystal growth and a method for releasing thermal stress of silicon carbide crystals. The crucible is a crucible in contact with the side surface of the prepared crystals, and the crucible has an annular non-closed splicing structure. The crucible for the crystal growth has the annular non-closed splicing structure, so that the crystals can be prevented from being hooped, hot stress concentrated in the crystals in the growth process of the crystals can be effectively released, the fracturing rate of the crystals can be reduced, and the finished product rate of the crystals can be increased.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: July 12, 2022
    Inventors: Pan Gao, Jun Xin, Haikuan Kong, Xuechao Liu, Yanqing Zheng, Erwei Shi
  • Patent number: 11384090
    Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: July 12, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Ruichao Shen, Yong He, Xuri Gao, Jun Ma, Xuechao Xing, Hui Cao, Joseph D. Panarese, Yat Sun Or